Lasmiditan succinate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for lasmiditan succinate and what is the scope of freedom to operate?
Lasmiditan succinate
is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lasmiditan succinate has eighty-five patent family members in forty-three countries.
One supplier is listed for this compound.
Summary for lasmiditan succinate
International Patents: | 85 |
US Patents: | 2 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 17 |
Patent Applications: | 1 |
DailyMed Link: | lasmiditan succinate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for lasmiditan succinate
Generic Entry Date for lasmiditan succinate*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for lasmiditan succinate
Paragraph IV (Patent) Challenges for LASMIDITAN SUCCINATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
REYVOW | Tablets | lasmiditan succinate | 50 mg and 100 mg | 211280 | 1 | 2024-01-31 |
US Patents and Regulatory Information for lasmiditan succinate
Expired US Patents for lasmiditan succinate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | ⤷ Sign Up | ⤷ Sign Up |
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | ⤷ Sign Up | ⤷ Sign Up |
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for lasmiditan succinate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Dominican Republic | P2019000139 | COMPOSICIONES Y MÉTODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F | ⤷ Sign Up |
Poland | 372845 | Pirydynoilopiperydyny jako związki agonistyczne 5-HT1F (PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS) | ⤷ Sign Up |
New Zealand | 534952 | Pyridinoylpiperidines as serotonin agonists and the use as medicaments for inhibition of neuronal protein extravasation, disorders due to dysfunction of the serotonin receptors and migraines | ⤷ Sign Up |
Canada | 2694410 | PYRIDINOYLPIPERIDINES UTILISEES COMME AGONISTES DE 5-HT1F (PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS) | ⤷ Sign Up |
Eurasian Patent Organization | 201991112 | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ С ПИРИДИНОИЛПИПЕРИДИНОВЫМИ АГОНИСТАМИ 5-HT1F | ⤷ Sign Up |
Jordan | P20190129 | تركيبات وطرق تتعلق بمواد مساعدة لـ 5-HT1F من بيريدينويل بيبريدين (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS) | ⤷ Sign Up |
Canada | 3043772 | HYDRATES DE 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYLE)-PYRIDIN-2-YL]-BENZAMIDE D'HEMISUCCINATE ET UTILISATIONS CONNEXES EN TANT QU'AGONISTE DE 5-HT1F (HYDRATES OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND USES THEREOF AS A 5-HT1F AGONIST) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |